Protein formulation and delivery

It has been said that dmg delivery represents the potential Achilles heel of biotechnology s peptide dmg industry. The reasons for this include the range of instabilities discussed above, the inherent low membrane transport by diffusion, because of molecular size and hydrophilicity, and often the need for temporal and site control of delivery. 

---

Protein Formulation and Delivery, edited by Eugene J. McNally... 

McNally, E. (ed.). 2000. Protein Formulation and Delivery. Marcel Dekker. 

Protein Formulation and Delivery, edited by Eugene J. McNally New Drug Approval Process Third Edition, The Global Challenge, edited by Richard A. Guarino... 

M. J. Pikal, Freeze-drying of proteins. Formulation and Delivery of Proteins and Peptides, (J. L. Cleland and R. Langer, eds.), American Chemical Society Symposium Series No. 567, 1994, pp. 120-133. 

Clark, A.R. Shire, S.J. Formulation of proteins for pulmonary delivery. In Protein Formulation and Delivery ... 

Clark AR, Shire SJ. In McNally EJ, ed. Protein Formulation and Delivery. New York Marcel Dekker, 2000 201. 

Salehi-Had, S. and W.M. Saltzman, Controlled intracranial delivery of antibodies in the rat, in J. Cleland and R. Langer, Protein Formulations and Delivery, Washington, DC ACS Symposium Series, 1994, pp. 278-291. 

Bnmmer P M, Koppenol S (2000). Chemical and physical considerations in protein and peptide stability. In E J McNally, (eds.). Protein Formulation and Delivery, Marcel Dekker, Inc. New York, pp. 5-69. 

Pikal MJ (1994). Freeze-drying of proteins, formulation and delivery of proteins and peptides. Am Chem Soc pp 120-133... 

---